Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490998 | 0.82 | UGT2B7 (0.36) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20780619 | 0.76 | — | — | |
| SCHEMBL83975 | 0.76 | NOS3 (0.50) | NPC1RAB9ASMN1; SMN2CHRNA7HTT | |
| SCHEMBL31222667 | 0.76 | NOS3 (0.50) | NPC1RAB9ASMN1; SMN2CHRNA7HTT | |
| SCHEMBL13602061 | 0.75 | CCR1 (0.46) | LMNANPC1RAB9ASMN1; SMN2TYR | |
| SCHEMBL2741630 | 0.73 | ESR1 (0.38) | LMNANPC1RAB9ASMN1; SMN2TYR | |
| SCHEMBL179333 | 0.73 | LMNA (0.50) | LMNANPC1RAB9ASMN1; SMN2TYR | |
| SCHEMBL10186987 | 0.73 | TAAR1 (0.30) | NFKB1HIF1A | |
| SCHEMBL10165324 | 0.72 | CHRNA7 (0.31) | CHRNA7 | |
| SCHEMBL84395 | 0.71 | TYR (0.40) | LMNANPC1RAB9ASMN1; SMN2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | claimed |
| CN-1210105-A | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | CN | claimed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | claimed |
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECHNOLOGY, LLC | 2023-05-11 | — | — | US | disclosed |
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-1539980-B1 | LIBRARY OF COMPLEXES COMPRISING SMALL NON-PEPTIDE MOLECULES AND DOUBLE-STRANDED OLIGONUCLEOTIDES IDENTIFYING THE MOLECULES | NUEVOLUTION AS (DK) | 2016-02-17 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| CN-1703397-A | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-11-30 | — | — | CN | disclosed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| CN-1103335-C | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | CN | disclosed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | disclosed |
| CN-1210105-A | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | CN | disclosed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144322-A1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | FOLH1, PSMA2, PSMA6 | LMNA 2847/4885NPC1 587/4885RAB9A 1678/4885 |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | LMNA 2623/4885NPC1 1748/4885RAB9A 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.